advanced non small cell lung cancer
Conditions
Interventions
to evaluate the proportion of renal toxicity in cisplatin-based chemotherapy with short hydration using mannitol
to evaluate the proportion of renal toxicity in cisplatin-based chemotherapy with short
Sponsors
Okayama University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: pathologically proven non small cell lung cancer stage IV or stage III without suitability for curative treatment or postoperative reccurent case combination chemotherapy using cisplatin plus 3rd generation anticancer drug at the age of 20 to 75 measurable tumor sites no prior chemotherapy no prior systemic anticancer therapy including palliative brain or bone irradiation within 1 week of proposed entry to this trial ECOG PS of 0 to 1 appropriate organ function acquisition of written informed consent
Exclusion criteria
Exclusion criteria: 1. pts who will receive CDDP of less than 75 mg/m²/day 2. pts with active co-morbidities including severe conditions of heart diseases, cerebrovascular diseases, gastric ulcers, severe infections, uncontrollable diabetes, psychlogicai diseases, and hearing loss. 3. pts with active interstitial lung diseases. 4. pts with symptomatic brain metastases. 5. pts with active other cancers detected within the past 3 years. 6. pts with massive pleural and cardiac effusion and ascites that need to be immediately treated 7. pts with using oral diuretics 8. pts who can not drink water more than 1L/day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility of mannnitol or furosemide forced diuresis of cisplatin-based chemotherapy with short hydration | — |
Countries
Japan
Contacts
Public ContactGo Makimoto
Okayama University Hospital Department of Repiratory Medicine
Outcome results
None listed